GlobeNewswire

Barloworld Equipment Innovates its Service with Librestream's Onsight

Dela

Librestream's Onsight platform brings expert remote capability to Barloworld Equipment

WINNIPEG, Manitoba, July 25, 2018 (GLOBE NEWSWIRE) -- Barloworld Equipment, southern Africa's leading Caterpillar dealer, has a reputation for excellence. The company is relentless in pursuit of its mission to deliver innovative solutions for exceptional customer performance through its people. To this end, Barloworld Equipment recently invested in Librestream's remote expert solution, Onsight. The solution will enable its field technicians to connect to remote expertise from any location and capture content for mentoring and later use. It will also provide technicians a safer way to perform inspections in the typically difficult field environments in which they operate.

"It was important to us to find an expert remote solution that provides the stability we need in the field while allowing our workforce to easily communicate cross-border. Not only will Onsight provide our teams with live remote mentoring, but also a way to quickly and efficiently get their job done for customers," said Barloworld Equipment's Charl Groenewald, Executive Head: Customer Fulfillment Services.

Barloworld Equipment is equipping its service teams with the Onsight Connect expert remote software as well as the Onsight rugged hardware products. A selection of these will be applied to the different service environments that teams typically operate in:

  • Onsight Cube , used for inspections at height or under vehicles, avoids field technicians moving into hazardous situations. Its thermal imaging capability also enables data collection on temperatures - mining equipment exhausts being an example.
  • Onsight Smartcam will have application in workshop situations, measuring and inspecting cracks or defects in equipment.
  • Onsight Hub, used exclusively with a field technician's borescope, assists with both inspections as well as mentoring of new technicians on the use of this equipment.

"Onsight is designed to empower workers by connecting them to their teams and the content they need to access," Kerry Thacher, CEO at Librestream said. "We are excited to be a part of Barloworld Equipment's innovative approach to enhance its customers' expectations and services."

About Barloworld Equipment
Barloworld Equipment is a division of Barloworld Limited, a multinational brand distribution company listed on the Johannesburg Stock Exchange.

Barloworld Equipment is the dealer for Cat earthmoving machines and Cat power systems in all its southern African territories - South Africa, Lesotho, Swaziland, Namibia, Botswana, Angola, Malawi, Mozambique, Zambia and the Democratic Republic of Congo's Katanga Province (in joint venture with Tractafric Equipment).

Additionally, Barloworld Equipment is the Cat dealer for Siberia and the Russian Far East.

Barloworld Equipment also operates in the United Kingdom and China.

Other Barloworld Group divisions comprise Barloworld Automotive and Barloworld Logistics.

Find more at www.barloworld-equipment.com and connect with us on LinkedInFacebook & Twitter.

About Librestream Technologies Inc.
Librestream develops digital transformation technology that improves service operations within the industrial sector. Deployed globally, the Onsight augmented reality service platform empowers workers to rapidly diagnose, inspect, and manage assets in even the most difficult field environments. The Onsight platform includes core AR capabilities including remote expert, digital work instructions and rich content access. Visit Librestream at www.librestream.com and connect with us on LinkedInFacebook & Twitter.

CONTACT INFORMATION

Press Contact:

Jacqui Janse van Rensburg
Communications Manager
Barloworld Equipment southern Africa
Tel: 011 301 4000
Email: JVRensburg1@barloworld-equipment.com

Marieke Wijtkamp
Vice President of Marketing & Client Services
Librestream Technologies Inc.
Tel: 204.487.0612 ext. 259
Email: marieke.wijtkamp@librestream.com

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/fc0d5439-e2d2-4c25-af87-5cecf99a5812




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Librestream Technologies Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Karolinska Development's portfolio company Aprea Therapeutics has received FDA Orphan Drug Designation and Fast Track Designation for APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, April 16, 2019. Karolinska Development's portfolio company Aprea Therapeutics has from FDA received an Orphan Drug Designation for APR-246 for the treatment of patients with Myelodysplastic Syndromes (MDS) having a TP53 mutation. In addition, FDA has also granted Fast Track Designation to APR-246 for treatment of MDS. Orphan Drug Designation is granted by the FDA Office of Orphan Products Development to advance the evaluation and development of safe and effective therapies for the treatment of rare diseases. The designation can provide development and commercial incentives for designated compounds and medicines, including eligibility for a seven-year period of market exclusivity in the U.S. after product approval, FDA assistance in clinical trial design, tax credits related to clinical trial expenses, and an exemption from FDA user fees. The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to addre

Karolinska Developments portföljbolag Aprea Therapeutics har fått särläkemedelsstatus och snabbspårstatus från FDA för APR-24616.4.2019 12:46:00 CESTPressmeddelande

STOCKHOLM, SVERIGE - 16 april 2019. Karolinska Development AB meddelar idag att portföljbolaget Aprea Therapeutics har av FDA fått särläkemedelsstatus för APR-246 för behandling av patienter med TP53-muterad myelodysplastiskt syndrom (MDS). Dessutom ger FDA bolaget snabbspårstatus (Fast Track Designation), för APR-246 för behandling av MDS. Amerikanska läkemedelsverket, FDA, ger särläkemedelsstatus till läkemedelskandidater för att snabba på utvärderingen och utvecklingen av säkra och effektiva behandlingar av ovanliga sjukdomar. Särläkemedelsstatus ger företag både regulatoriska och kommersiella incitament genom att läkemedlet får marknadsexklusivitet på den amerikanska marknaden i sju år efter marknadsgodkännande samtidigt som företaget får stöd från FDA när det gäller designen av kliniska prövningar, skatteförmåner för kostnader kopplade till kliniska prövningar och avgiftsbefrielse från FDA. FDA:s snabbspår underlättar utvecklingen av läkemedel som är avsedda för att behandla allva

Bergman & Beving AB: Bergman & Beving förvärvar KGC10.4.2019 14:00:00 CESTPressmeddelande

Pressmeddelande Bergman & Beving förvärvar KGC Bergman & Beving har idag tecknat avtal om förvärv av samtliga aktier i KGC Verktyg & Maskiner AB. KGC, med säte i Älvsjö, har i mer än 60 år utvecklat och levererat kvalitetsverktyg och tillbehör för murning och plattsättning i det egna varumärket KGC. Bolaget omsätter cirka 80 MSEK per år, och har 24 anställda. "KGC är ett ledande varumärke med högt anseende hos murare och plattsättare och har en mycket stark ställning på den svenska marknaden", säger Pontus Boman, VD och koncernchef. Tillträde beräknas ske den 1 maj 2019 och förvärvet bedöms ha en marginellt positiv påverkan på Bergman & Bevings resultat per aktie under innevarande räkenskapsår. Stockholm den 10 april 2019 Bergman & Beving AB (publ) För ytterligare information kontakta: Pontus Boman, VD & Koncernchef, telefon 010-454 77 00 Peter Schön, CFO, telefon 070-339 89 99 Denna information lämnades, genom ovanstående kontaktpersoners försorg, för offentliggörande den 10 april 201

Bergman & Beving AB: Bergman & Beving acquires KGC10.4.2019 14:00:00 CESTPressmeddelande

Press release Bergman & Beving acquires KGC Bergman & Beving has today signed an agreement to acquire all shares in KGC Verktyg & Maskiner AB. KGC, based in Älvsjö, has for more than 60 years developed and delivered quality tools and accessories for bricklayers and tilers in its own brand KGC. The business has a turnover of approximately SEK 80 million per year, and has 24 employees. "KGC is a leading brand with high reputation among bricklayers and tilers and has a very strong position in the Swedish market," says Pontus Boman, President and CEO. The closing is taking effect on 1 May 2019 and the acquisition is expected to have a marginal positive impact on Bergman & Beving's earnings per share during the current fiscal year. Stockholm, 10 April 2019 Bergman & Beving AB (publ) For further information, please contact: Pontus Boman, President & CEO, Tel: +46 10 454 77 00 Peter Schön, CFO, Tel: +46 70 339 89 99 The information was submitted for publication, through the agency of the cont

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

Karolinska Development's portfolio company Aprea presents promising results with APR-246 in combination with immuno-oncology agents3.4.2019 14:00:00 CESTPressmeddelande

STOCKHOLM, April 3, 2019. Karolinska Development's portfolio company Aprea today presents results from studies with APR-246 in combination with immune checkpoint blockade. The results show that APR-246 can improve the effect of immuno-oncology agents. Karolinska Development portfolio company Aprea Therapeutics announced today the results of studies with APR-246 in combination with immune checkpoint blockade. The results were presented by researchers from Memorial Sloan Kettering Cancer Center at the 2019 AACR Annual Meeting in Atlanta. The studies collectively support a role for p53 activity in the tumor microenvironment and suggest that stabilization of the tumor suppressor protein, p53, by APR-246 can enhance anti-tumor immune response, particularly when combined with immuno-oncology agents. The studies characterized changes in the tumor immune microenvironment in melanoma and colorectal cancer in vivo models when treated with APR-246 and immuno-oncology agents, either alone or in co

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum